Fig. 3.
SARS (N) DNA vaccine induces in vivo human CTL against SARS CoV in the SCID-PBL/hu human immune systems. 4 × 107 PBL from healthy human volunteers were administered i.p. into IL-2 receptor γ-chain disrupted NOD SCID mice [IL-2R (−/−) NOD-SCID], and SCID-PBL/hu mice were constructed 50 μg of SARS (N) DNA vaccine or 50 μg of SARS (S) DNA vaccine. 1 × 105 spleen cells from SCID-PBL/hu were cultured with 10 μg of recombinant SARS (N) protein for 72 h. IFN-γ production in the culture supernatant was assayed using ELISA.